IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers strains under the Roma, Dairy Queen, London, Tel Aviv, Paris, and Pandora Box brands; and CBD oil products under the IMC brand. The company also offers its intellectual property related services to the medical cannabis industry. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.
IPO Year:
Exchange: NASDAQ
Website: imcannabis.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/5/2021 | $8.00 | Buy | ROTH Capital |
| 7/14/2021 | Buy | Desjardins | |
| 7/14/2021 | $10.50 | Buy | Desjardins |
ROTH Capital initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $8.00
Desjardins initiated coverage of IMC Mortgage Co with a rating of Buy
Desjardins initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $10.50
Alliance Global Partners initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $10.00
SC 13G - IM Cannabis Corp. (0001792030) (Subject)
SC 13D/A - IM Cannabis Corp. (0001792030) (Subject)
SC 13G/A - IM Cannabis Corp. (0001792030) (Subject)
SC 13G - IM Cannabis Corp. (0001792030) (Subject)
Q4 2024 Caps a Year of Strategic and Operational Improvements for IMC with 25% Revenue Growth, 42% decrease in Operating Expenses, and $0.5M Adjusted EBITDA Profit TORONTO and GLIL YAM, Israel, March 31, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, is pleased to announce its financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all amounts are reported in Canadian dollars and are compared to the quarter ended December 31, 2023. The Company's audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 and accompanying manage
TORONTO and GLIL YAM, Israel, March 20, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company," "IMCannabis," or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the fourth quarter and full year 2024 ended December 31, 2024, on Monday, March 31, 2025 before the market opens. The Company will host a zoom web conference on the same day at 9:00a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a
IMC pairs a +12% increase in revenue with a -16% decrease in the total operating expenses, building a solid foundation to deliver in 2025. TORONTO and GLIL YAM, Israel, Nov. 14, 2024 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial results today for the third quarter ended September 30, 2024. All amounts are reported in Canadian dollars and compared to the quarter ended September 30, 2023, unless otherwise stated. Q3 2024 Financial Highlights +12% increase in Revenue to $13.9M vs. $12.4M in Q3, 2023. Adjusting for the revocation of the Oranim deal, increases the revenue to +51% or $4.7M vs
IMC Germany delivers +200% in sales in first three months after German legalization, while overall revenue grows 12% vs Q2 2023 TORONTO and GLIL YAM, Israel, Aug. 14, 2024 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2024. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2023, unless otherwise stated. Q2 2024 Financial Highlights 12% Revenue increase to $14.8M vs. $13.2M in Q2 2023 129% increase in IMC Germany sales vs. Q2 2023 to $3.5M. IMC Germany sales now make up 24% of the entire Company r
TORONTO and GLIL YAM, Israel, Aug. 6, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter 2024 ended June 30, 2024, on Wednesday, August 14, 2024, before the market opens. The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the
IMC prepares for accelerated growth after legalization in Germany and recovers from the impact of the Israel-Hamas war. TORONTO and GLIL YAM, Israel, May 8, 2024 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial results today for the first quarter ended March 31, 2024. All amounts are reported in Canadian dollars and compared to the quarter ended March 31, 2023, unless otherwise stated. Q1 2024 Financial Highlights 13% Revenue increase vs. Q4 2023 of $12.1M vs. $10.7M and 4% decrease vs. Q1 2023 of $12.5M 125% Gross profit increase vs. Q4 2023 of $1.8M vs. $0.8 and 39% Gross profit decrea
TORONTO and GLIL YAM, Israel, May 1, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the first quarter 2024 ended March 31, 2024, on Wednesday, May 8, 2024, before the market opens. The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the call
TORONTO and GLIL YAM, Israel, March 28, 2024 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial and operational results for the year ended December 31, 2023, the highlights of which are included in this news release. All figures are reported in Canadian dollars. The Company's full set of consolidated audited financial statements for the years ended December 31, 2023 and 2022 (the "Annual Financial Statements") and accompanying management's discussion and analysis (the "Annual MD&A") can be accessed by visiting the Company's website at https://investors.imcannabis.com/, and its profile pages o
TORONTO and GLIL YAM, Israel, March 20, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the fourth quarter and full year 2023 ended December 31, 2023, on Thursday, March 28, 2024 before the market opens. The Company will host a zoom web conference on the same day at 9:00a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live,
IMC remains singularly focused on accelerating its path to profitability through active cost management and margin improvement while maintaining sales. TORONTO, and GLIL YAM, Israel, Nov. 13, 2023 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial results today for the third quarter ended September 30, 2023. All amounts are reported in Canadian dollars and compared to the quarter ended September 30, 2022, unless otherwise stated. The full set of unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2023 (the "Q3 FS"), and the accompan
TORONTO and GLIL YAM, Israel, April 11, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IM Cannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, today announced the following corporate updates. Nasdaq Notification Letter The Company has received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") dated April 9, 2025, notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5550(b)(1). Nasdaq Listing Rule 5550(b)(1) (the "Listing Rule") requires companies listed on the Nasdaq Capital Market to maintain a minimum of US$2.5 million in stockholders'
Q4 2024 Caps a Year of Strategic and Operational Improvements for IMC with 25% Revenue Growth, 42% decrease in Operating Expenses, and $0.5M Adjusted EBITDA Profit TORONTO and GLIL YAM, Israel, March 31, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, is pleased to announce its financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all amounts are reported in Canadian dollars and are compared to the quarter ended December 31, 2023. The Company's audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 and accompanying manage
TORONTO and GLIL YAM, Israel, March 20, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company," "IMCannabis," or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the fourth quarter and full year 2024 ended December 31, 2024, on Monday, March 31, 2025 before the market opens. The Company will host a zoom web conference on the same day at 9:00a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a
TORONTO and GLIL YAM, Israel, Jan. 17, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, announces that it has changed its auditor from Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global (the "Predecessor Auditor") to Fahn Kanne & Co. Grant Thornton Israel (the "Successor Auditor") effective January 16, 2025. The Predecessor Auditor resigned effective January 16, 2025, at the Company's request, and the Company's board of directors, upon the audit committee's recommendation, appointed the Successor Auditor to fill the resulting vacancy until the close of the next annua
IMC pairs a +12% increase in revenue with a -16% decrease in the total operating expenses, building a solid foundation to deliver in 2025. TORONTO and GLIL YAM, Israel, Nov. 14, 2024 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial results today for the third quarter ended September 30, 2024. All amounts are reported in Canadian dollars and compared to the quarter ended September 30, 2023, unless otherwise stated. Q3 2024 Financial Highlights +12% increase in Revenue to $13.9M vs. $12.4M in Q3, 2023. Adjusting for the revocation of the Oranim deal, increases the revenue to +51% or $4.7M vs
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO and GLIL YAM, Israel, Nov. 12, 2024 /CNW/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that, further to its press release dated October 4, 2024 (the "October 4 Release"), the Company has closed its previously announced non-brokered private placement offering (the "Offering") effective today (the "Closing Date") through the issuance of 742,517 Units for gross proceed of C$2,138,448.96.
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO and GLIL YAM, Israel, Oct. 4, 2024 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that it intends to undertake a non-brokered private placement offering of up to US$1,613,000 through the sale of approximately 625,000 units (each, an "Unit") at a price per Unit (the "Offering Price") calculated on the basis of the deemed price per common shares in the capital of the Company (
TORONTO and GLIL YAM, Israel, Oct. 2, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that the preliminary sales results in Germany by its German subsidiary, Adjupharm GmbH ("IMC Germany"), for the third quarter of 2024 have significantly exceeded expectations, showing a remarkable 50% increase in revenue compared to the second quarter, where IMC Germany sold about CAD$ 3.5M. This outstanding growth demonstrates IMC Germany's successful execution of its strategic initiatives and strong market demand for its products. Since the partial lega
TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company's board of directors (the "Board") effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company's commitment to driving growth while focusing on sustainable profitability. "We are thrilled to welcome Shmulik to our Board of Directors," said Oren Shuster, Chief Executive Officer of
IMC Germany delivers +200% in sales in first three months after German legalization, while overall revenue grows 12% vs Q2 2023 TORONTO and GLIL YAM, Israel, Aug. 14, 2024 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2024. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2023, unless otherwise stated. Q2 2024 Financial Highlights 12% Revenue increase to $14.8M vs. $13.2M in Q2 2023 129% increase in IMC Germany sales vs. Q2 2023 to $3.5M. IMC Germany sales now make up 24% of the entire Company r
6-K - IM Cannabis Corp. (0001792030) (Filer)
6-K - IM Cannabis Corp. (0001792030) (Filer)
6-K - IM Cannabis Corp. (0001792030) (Filer)
20-F - IM Cannabis Corp. (0001792030) (Filer)
6-K - IM Cannabis Corp. (0001792030) (Filer)
6-K - IM Cannabis Corp. (0001792030) (Filer)
6-K - IM Cannabis Corp. (0001792030) (Filer)
6-K - IM Cannabis Corp. (0001792030) (Filer)
6-K - IM Cannabis Corp. (0001792030) (Filer)
6-K - IM Cannabis Corp. (0001792030) (Filer)
TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company's board of directors (the "Board") effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company's commitment to driving growth while focusing on sustainable profitability. "We are thrilled to welcome Shmulik to our Board of Directors," said Oren Shuster, Chief Executive Officer of
TORONTO and GLIL YAM, Israel, Oct. 10, 2023 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Uri Birenberg will join the company's leadership team as Chief Financial Officer effective October 10, 2023. This appointment strengthens IMC's financial leadership and strategic direction for achieving sustainable profitability. "We're delighted to welcome Uri as our new Chief Financial Officer at IMC. His impressive track record and extensive experience with large scale international organizations, as well as with startups, make him an outstandin
Oren Shuster remains Chief Executive Officer and Director of IM Cannabis Corp.; other managerial changes include the promotion of Yael Harrosh to Chief Legal and Operations Officer of IM Cannabis Corp.TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / January 13, 2022 / IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE:IMCC)(NASDAQ:IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany today announced the appointment of Rinat Efrima as the new Chief Executive Officer of IMC Holdings Ltd. ("IMC Holdings"), the Company's wholly-owned Israeli subsidiary. Ms. Efrima will join the Company in the first quarter of 2022. In addition, Ya
TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / August 3, 2021 / IM Cannabis Corp. ("IMC" or the "Company") (CSE:IMCC), (NASDAQ:IMCC), a multi-country operator ("MCO") in the medical and adult-use recreational cannabis sector with operations in Israel, Germany and Canada, is pleased to announce the voting results from its annual general and special meeting of shareholders held on Wednesday July 28, 2021 (the "Meeting").A total of 37,108,584 common shares of the Company were voted at the Meeting, representing 65.03% of the Company's issued and outstanding common shares as of the date of the Meeting. Shareholders voted to approve all matters brought before the Meeting including fixing the numb